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To date, preeclampsia (PE) is still a leading cause of fetal and maternal morbidity and 
mortality1. Even if many progress have been made in these last decades, its aetiology 
is still largely unknown2. 
It is debated if preeclampsia should be considered as a unique disease, presenting a 
continuum of clinical expression and severity, which appear to be worse as soon as 
PE symptoms arise during pregnancy or as a syndrome, characterized by different 
clinical phenotypes3. An increasing number of scientific evidences have already 
established two possible distinct pathogenic mechanisms of PE: on one side we have 
a placental dysfunction that originates at the very beginning of placentation and is 
consequently associated with fetal growth restriction (Burton et al, 2010) and on the 
other side, late changes in placental function associated with the size of the term 
placenta restricting intervillous perfusion, this type of placental lesion is associate 
with appropriate for gestational age newborn (AGA) or even large for gestational age 
newborns (LGA). Both lesions yield a syncytio trophoblast stress (STB) disorder 
with by-products that impact the maternal endothelial function (Redman et al, 2014). 
In addition to this both conditions might add to a pre-existing maternal systemic 
inflammatory pattern (Borzychowski et al, 2006; Steegers et al, 2010) usually 
associated with a maternal metabolic syndrome. Among the co-factors of this 
syndrome dyslipidaemia is made more severe by the typical energy metabolism of 
pregnancy possibly facilitating an abnormal increase in spiral arteries atherosis (Staff 
et al, 2014). Maternal cardiovascular adaptation in these different clinical phenotypes 
seems to be characterized by different cardiac output and total peripheral resistances, 
although controversial findings need further research (Valensise et al, 2008;   
Melchiorre et al 2014, Circulation). 
 
PREECLAMPSIA TODAY 
In spite of these two predominant models of placental dysfunction and the insight 
into the contributory predisposition of maternal conditions, clinical diagnosis of PE is 
still based on non-specific symptoms and signs (hypertension and proteinuria) as they 
were determined prior to any biophysical and biochemical diagnostic tool that can be 
routinely applied in clinical obstetrics such as fetal biometry, Doppler interrogation 
of uterine and umbilical arteries (Ferrazzi et al, 2015) and placental markers of 
integrated STB oxidative stress. (NICE, 2010; WHO Guidelines, 2011; ACOG, 
2013). These basic old criteria are now integrated with sign and symptoms of all 
possible complications arising from a generalized endothelial dysfunction associated 
with any symptoms and/or sign of organ failure, other than proteinuria (Royal 
College of Obstetrics and Gynaecology, 2006; Society of Obstetric Medicine of 
Australia and New Zealand, 2008; Society of Obstetricians and Gynaecologists of 
Canada, 2008; American Society of Hypertension, 2008). Some (Magee et al, 2014), 
but not all guidelines, consider fetal  growth restriction as marker of damage that 
associated with maternal hypertension fall into the realm of PE in addition to 
maternal symptoms and maternal end-organ dysfunction.  Recently even the 
prognostic factor of proteinuria has been “downgraded”. Once proteinuria is no 
longer the sole co-factor that added to hypertension qualify a clinical condition for 
preeclampsia, then a larger definition could be welcomed for this syndrome and 
Hypertensive Disorders of Pregnancy (HDP) might serve for this role. 
 
EPIDEMIOLOGY  
In Europe Hypertensive Disorders of Pregnancies (HDP) affect the 4-8 % of 
pregnancies, representing one of the main complication of pregnancy (Steegers et al, 
2010). Among these preeclampsia constitutes a sub group the prevalence of which is 
largely dependent on how strict are the prenatal controls and subsequent clinical 
interventions such as antihypertensive drugs, work leave, induction of labor for 
hypertension, delivery for fetal growth restriction, and above all how severe is the 
burden of maternal obesity and truncal obesity at a country level. In Europe where a 
reasonably strict control of pregnancy is offered to the universe of pregnant women 
the severe evolution of hypertension not associated with IUGR is rare, and the most 
severe form is represented by HDP associated with IUGR.  Worldwide, the killer 
among HDPs is preeclampsia not associated with early placental dysfunction and 
IUGR (Conde-Agudelo et al, 2000; Lozano et al, Lancet 2010), the early symptoms 
of HDP are not screened and pregnant women consult medical personnel late or are 
admitted to hospitals when in severe conditions with organ damage far beyond the 




CONTRIBUTION OF PlGF AND OF sFlt-1. 
At the beginning of this last decade, different studies discovered that women affected 
by preeclampsia show an unbalanced proportion of anti-angiogenic and pro-
angiogenic soluble plasmatic factors13 (Cetin 2010). Excessive placental production 
of soluble fmf-like tyrosine kinase receptor-1 (sFlt-1), an antagonist of vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF), contributes to 
the pathogenesis of PE.  
An increased sFlt-1/PlGF ratio is more pronounced in early-onset rather than late 
onset disease and is associated with severity of clinical disorder; furthermore, the 
unbalanced of PlGF and sFlt-1 causes vasoconstriction and endothelial damage that 
may lead to fetal growth restriction and preeclampsia14,15,16.  
Steps forward were also made thanks to the implementation of a elettrochemo 
luminescence method for the dosage of the anti- and pro- angiogenic factors ratio in 
an automated, rapid, precise, reproducible test17,18.  
Moreover, the sFlt-1/PlGF ratio has been approved as a diagnostic aid for 
preeclampsia in conjunction with other clinical findings18 and was recently 
incorporated into German guidelines19. Also the NICE, recently established that the 
triage PlGF test and the Elecsys immunoassay sFlt-1/PlGF ratio, used with standard 
clinical assessment, are recommended as diagnostic aid for preeclampsia in women 
between 20 and 34 weeks of gestation plus 6 days (16 December 2015, article in 
press). 
Extensive research has been published demonstrating the usefulness of angiogenic 
markers in both diagnosis and subsequent prediction and management of PE and 
placenta-related disorders20. A recent article published by the New England Journal 
of Medicine provide evidences for an helpful cut off for the ratio sFlt-1 and PlGF, 
that identifies women at risk of preeclampsia weeks before its clinical onset21. It is a 
prospective, multicenter, observational study that identifies a sFlt-1/PlGF ratio cut-
off of 38 as having an important predictive value: a ratio of 38 or lower has a 
negative predictive value, for the diagnosis of PE in the subsequent week, of 99,3%, 
with 80% sensitivity and 78,3% of specificity. The positive predictive value of a sFlt-
1/PlGF ratio above 38 for a diagnosis of PE within 4 weeks is 36,7%, with 66,2% 
sensitivity and 83,1% specificity. 
That is why, the measurement of the sFlt-1/PlGF ratio has the potential to become an 
additional tool in the early diagnosis and management of PE,  
Therefore, it is now essential to evaluate the clinical implication of this test, together 
with its social, legal, economical and ethical implications. 
 
CONSENSUS STATEMENT  
This panel of experts suggested the preconception identification of the main risk 
factors of HDP, such as obesity, hyperglycaemia, dyslipidemia, chronic hypertension, 
congenital and acquired thrombophilic conditions, autoimmune disease, and chronic 
renal disease is fundamental. These conditions, when possible, should be removed or 
minimized prior to conception by an adequate information about life style and 
healthy nutritional regimen. Accurate family and personal history and laboratory 
diagnosis should be pursued in case of  clinical conditions that could require ad hoc 
prophylactic or therapeutic regimens prior to conception. 
In early gestation, predictive examinations should be added to clinical history in 
order to identify the subset of pregnant women who deserves closer monitoring and 
prophylactic intervention.  
Prenatal and postnatal attempt should be pursued for adequate assessment of 
placental and fetal involvement in cases of HDP, so that to add fetal medicine 
contributes to maternal medicine standard diagnosis and therapy. 
Severe and severe early cases should be referred to tertiary centres for maternal and 
fetal intensive  monitoring and therapy. 
Special attention should be aimed to disentangle the role of sFlt-1 and PlGF within 
the different clinical phenotypes of this syndrome.  sFlt-1 and PlGF and sFlt-1/PlGF 
ratio, varies consistently in normal gestations from 30-32 weeks to term showing how 
in normal pregnancies the pro-angiogenic factors progressively decline and blocking 
factors progressively increase (Levine et al, 2004). This is expected given the growth 
trajectory of human placenta. These angiogenic factors are altered both in early 
gestation in cases that later will develop HDP with IUGR and become altered in 
women that develop HDP and PE with AGA and LGA fetuses. 
Taking into account this possible different etiopathogenesis, this test could be also 
used to differentiate between intrauterine growth restricted foetuses and small for 
gestational age (SGA) neonates. Nowadays, even if the unbalanced proportion of 
these two plasmatic factors in women affected by preeclampsia is known, their exact 
role in the development of hypertensive disorders of pregnancy is not completely 
understood. 
 
PURPOSE OF FOCUS GROUP: 
The purpose of this focus group is to promote the evaluation of the clinical utility of 
sFlt-1/PlGF ratio at the italian country level as regards: 
 
1. Patients with risk factors for preeclampsia (previous PE, chronic 
hypertension, chronic kidney disease, type 1-2 diabetes, thrombophilia, 
autoimmune disease, altered uterine arteries Doppler ultrasound after 24 
gestation weeks). 
2. Patients with non-specific signs and symptoms of PE: “suspected” PE22. 
3. Patients with blown PE. 
 
 POSSIBLE SFLT-1/PLGF RATIO APPLICATIONS: 
 
1. Prediction of different phenotypes of HDP, especially as regards PE 
according to its definition  by the Canadian Guidelines. Prediction in the 
first trimester is of major importance  for the development of future studies 
on preventing therapies. 
2. Prediction of recurrence among patients with previous HDP 
3. Triage of patients suffering from gestational hypertension 
4. Evaluation of HDP degree/severity in patients with clinical disease 
5. Prediction of possible adverse maternal and fetal outcomes. 
 
1- Prediction during the first trimester 
The additional measurement of the sFlt-1/PlGF ratio has been shown to 
improve the sensitivity and specificity of Doppler measurement in predicting 
PE23,24,25,26,27, supporting its implementation in screening algorithms. 
Furthermore, considering that no preventive or therapeutic strategy is yet 
available, with the exception of low dose acetylsalicylic acid, which has 
moderate preventive effect in high-risk pregnancies after the first trimester28, 
clinical experience suggests that early detection and monitoring are beneficial7. 
An Italian multicenter trial about PE predictivity would be useful, considering 
the different clinical phenotypes (HDP-IUGR, HDP-AGA), in order to 
evaluate if the test would be useful only among high risk population or also 
among low risk population and to evaluate its utility also for the prediction of 
intrauterine growth restriction. 
 
2- Prediction or exclusion of new onset or recurrence among patients with 
risk factors for PE. 
sFlt-1/PlGF ratio dosage may be useful for pregnant outpatients presenting 
with risk factors for PE (previous PE, chronic hypertension, chronic kidney 
disease, type 1 diabetes, lupus, thrombophilia, autoimmune disease, altered 
uterine arteries Doppler velocimetry after 24 gestation weeks), especially for 
its elevated negative predictive value, which excludes the onset of PE in the 
subsequent week. 
 
3- Triage of patients suffering from gestational hypertension. 
In tertiary care centres, for outpatients or at the obstetrical emergency room, 
the ratio dosage may be applied in the triage of pregnant patient presenting 
with gestational hypertension, also to evaluate their need for hospitalization 
and the subsequent clinical management, especially if: 
o non-specific signs or symptoms of PE are described (epigastric pain, 
severe swelling, face edema, sudden weight gain, headache, visual 
disturbances, low platelets, transaminases augmentation); 
o differential diagnosis with other clinical forms characterized by 
proteinuria is needed (e.g., chronic kidney disease with first 
manifestation during pregnancy); 
o differential diagnosis between previous chronic pathology and PE 
overlap is needed; 





4- Evaluation of disease severity. 
In hospitalized preeclamptic women, the ratio dosage can be repeated after 48 
hours to evaluate its trend: a sudden increase may point out a rapid worsening 
of the patient’s condition, while the finding of a stable value can reassure the 
physician the patient will not deteriorate rapidly and allows test repetition at 
two weeks29.  
 
5- Prediction of adverse maternal and foetal outcomes. 
In hospitalized preeclamptic women, a repeat measurement of the sFlt-1/PlGF 
ratio may help to distinguish whether a patient is at moderate, high or very 




Despite our knowledge about sFlt-1/PlGF ratio, more data are needed in order to 
improve the clinical applicability of the test. In order to obtain this result, further 
research should be use a different classification of hypertensive disorders of 
pregnancy considering the possible different pathogenic mechanisms which lay under 
different clinical forms of PE.  
Moreover, new trials will be helpful to evaluate if the routinely use of this test could 
improve the clinical management of preeclamptic women, avoiding unnecessary 
hospital admissions.  
Finally, the diffusion of scientific data and their implementation in defined guidelines 
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